Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments

Anusha Pusuluri,Debra Wu,Samir Mitragotri

DOI: https://doi.org/10.1016/j.jconrel.2019.04.020

IF: 11.467

2019-07-01

Journal of Controlled Release

Abstract:<h2>Abstract</h2><p>The tumor environment has been shown to employ several immunosuppressive mechanisms to evade cancer treatments. While immunotherapies actively reverse such mechanisms, and polarize the immune system against malignant cells, combination of immunotherapy with certain chemotherapeutics leads to increased efficacy compared to each treatment alone. At low doses, chemotherapy demonstrates several immunogenic effects that can favorably potentiate immunotherapies. However, the clinical benefits of such therapies are confounded by the treatment complexity and marginal improvements. The highly complex relationship between chemotherapeutic drug dosing and subsequent immunological consequences is often generalized, thus limiting their understanding and potential. Also, simultaneous monitoring of the immunological impact is crucial for superior synergies during the optimization of chemotherapeutic combinations or usage of novel delivery systems. In this review, we summarize the existing literature on the immunological outcomes of chemotherapies administered individually, in combination regimens, and in formulation that use novel delivery agents. Further, we discuss the relevance of key parameters including dosage, schedule, and tumor models, and describe their clinical implications, with an emphasis on approaches and evaluations that are crucial for developing effective immune-stimulating therapies.</p>

pharmacology & pharmacy,chemistry, multidisciplinary